Titan Biotech Ltd (BSE: 524717) is a New Delhi, Delhi-based company in the Food and Feed Ingredients industry. With a market capitalisation of ₹1,916 Cr, it ranks #1,268 by market cap among the 6,197 Indian listed companies on FinBizNet, and #1 of 2 in Food and Feed Ingredients. At ₹366.65 (as of 16 Nov 2026), the share price is 17.5% below its 52-week high of ₹444.52 and 154.2% above its 52-week low of ₹144.26. The share price is up 135.6% over one year and up 17.1% over three months.
| Current Price | ₹366.65 |
|---|---|
| Market Cap | ₹1,916 Cr |
| BSE Code | 524717 |
| Sector | Materials > Chemicals > Speciality Chemicals |
| Sub-Industry | Specialty Chemicals > Food and Feed Ingredients |
| P/E Ratio | 64.3 |
| Return on Equity | 17.84% |
| Return on Assets | 10.79% |
| 52-Week Range | ₹144.26 – ₹444.52 |
| 1-Year Price Change | +135.6% |
| 3-Month Price Change | +17.1% |
| Beta (1Y) | -0.85 |
| Dividend Yield | 0.11% |
| Headquarters | New Delhi, Delhi |
| Website | titanbiotechltd.com |
| Revenue | ₹59 Cr |
|---|---|
| Net Profit | ₹9 Cr |
| Net Margin | 16.0% |
| EPS (Basic) | ₹2.29 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Titan Biotech Ltd reported revenue of ₹59 Cr in Q1 FY27, up 27.2% from ₹47 Cr in Q1 FY26 and up 21.2% from ₹49 Cr in Q4 FY26. It posted a net profit of ₹9 Cr for the quarter, against a net profit of ₹6 Cr in Q1 FY26 (up 53.6%). Across the 6 quarters from Q4 FY25 to Q1 FY27, quarterly revenue ranged from ₹35 Cr (Q4 FY25) to ₹59 Cr (Q1 FY27). The company was profitable in each of these 6 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q1 FY27 | ₹59 Cr | ₹9 Cr | 16.0% |
| Q4 FY26 | ₹49 Cr | ₹7 Cr | 13.4% |
| Q3 FY26 | ₹57 Cr | ₹8 Cr | 13.9% |
| Q2 FY26 | ₹54 Cr | ₹7 Cr | 12.6% |
| Q1 FY26 | ₹47 Cr | ₹6 Cr | 13.2% |
| Q4 FY25 | ₹35 Cr | ₹4 Cr | 10.7% |
Standalone figures (₹ crore, XBRL filings).
Delivery averaged 58.2% of traded volume across 15 BSE sessions (21 Oct 2026 – 13 Nov 2026).
Titan Biotech Limited engages in the manufacture and sale of biological products in India and internationally. It offers food ingredients, including hydrolyzed vegetable protein, yeast extract powder, calcium propionate powder, potassium sorbate, and calcium lactate; collagen and protein products, such as wheat hydrolysate protein, corn hydrolysate protein, bovine collagen peptide, collagen peptide, fish collage, undernatured chicken collagen type II, mucopolysaccharides, chicken protein isolate, soya protein isolate, and pea protein isolate; and brown rice protein, milk protein, protein hydrolysate, bovine cartilage extract, L-glutathione, cow colostrum powder, collagen peptides, whey protein, sodium caseinate, chondroitin sulphate, and hyaluronic acid. The company also provides coenzyme Q10, glucosamine KCL/HCL, methyl sulfonyl methane, chelated minerals, and peptone; OX bile extract, cholic acid, cerebroprotein hydrolysate, and iron protein succinylate; medicinal yeast and brewer ye
1. Biological Goods-This segment engages in the manufacture and distribution of biological products, including biological peptones and extract, and dehydrated culture media.
1. Biological Goods-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Titan Biotech Ltd | ₹1,916 Cr | 64.3 | 17.84% | ₹59 Cr | +135.6% |
| Vidhi Specialty Food Ingredients Ltd | ₹1,559 Cr | 31.8 | 15.57% | ₹137 Cr | -4.3% |
Listed by market capitalisation. Ratios are shown for context only.
Titan Biotech Ltd is trading at ₹366.65, with a market capitalisation of ₹1,916 Cr.
Titan Biotech Ltd operates in the Materials > Chemicals > Speciality Chemicals space (Specialty Chemicals > Food and Feed Ingredients).
Titan Biotech Ltd has a P/E of 64.3 and a return on equity of 17.84%.
Titan Biotech Ltd is listed on the BSE under the scrip code 524717.
Titan Biotech Ltd's share price is up 135.6% over one year and up 17.1% over three months. Its 52-week range is ₹144.26 to ₹444.52.
In Q1 FY27, Titan Biotech Ltd reported revenue of ₹59 Cr and net profit of ₹9 Cr, with basic EPS of ₹2.29 (standalone, parsed from the company's exchange filing).
Titan Biotech Ltd reported revenue of ₹59 Cr in Q1 FY27, up 27.2% from ₹47 Cr in Q1 FY26 and up 21.2% from ₹49 Cr in Q4 FY26.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.